Gameto has raised $117.0M in total across 5 funding rounds.
Gameto's investors include ARCH Venture Partners, Atomic, Bascom Ventures, Coatue, Future Ventures, Insight Partners, Khosla Ventures, NFX, Overwater Ventures, RA Capital, TitletownTech, Two Sigma Ventures.
Gameto is a biotechnology company engineering cell-based therapeutics to address unmet needs in women's reproductive health, including infertility, IVF, egg freezing, ovarian disease, and menopause.[1][3][4] Its lead product, Fertilo, uses induced pluripotent stem cell (iPSC)-derived ovarian support cells to make IVF shorter, safer, and more effective by maturing eggs outside the body, with FDA clearance for clinical testing and the first baby born using this iPSC technology.[3][4] Gameto serves women and families facing reproductive challenges, solving problems like the grueling IVF process amid a global infertility crisis through its proprietary cell engineering platform.[1][3] Founded in 2020, the company has raised over $127M (including a $44M Series C in 2025), achieved Technology Pioneer status from the World Economic Forum in 2023, and holds 8 patents in developmental biology, stem cells, and assisted reproductive technology, signaling strong growth momentum.[1][2][4]
Gameto was founded in 2020 by physician-scientist Dina Radenkovic (CEO) and serial entrepreneur Martin Varsavsky (Chairman), blending medical expertise with proven business scaling in telecom and renewables.[1][4][5] Radenkovic, a former Forbes Under 30 alumna, and Varsavsky—who built Spain's second-largest telecom (Jazztel) and other ventures—launched the company in New York and Madrid (with operations in Austin) to tackle women's health gaps using modern cell engineering.[1][2][4][5] The idea emerged from frustration with outdated IVF methods and underinvestment in reproductive health; early traction included World Economic Forum recognition in 2023, FDA clearance for Fertilo trials, and rapid funding to $83M+ by 2025, culminating in clinical milestones like the first iPSC-derived baby.[1][2][3][4]
Gameto stands out in biotech through its focus on female reproductive cells, leveraging a proprietary platform for scalable innovation:
Gameto rides the tech-bio convergence wave, applying cell engineering and iPSCs to a $50B+ fertility market long neglected despite rising infertility rates from aging populations and environmental factors.[1][3][4] Timing aligns with FDA's push for innovative reproductive tech, post-COVID fertility surges, and women's health investment boom (e.g., menopause drugs gaining traction).[3][4] Market forces like IVF demand (2M+ cycles/year globally) and tech-bio funding (Gameto's $127M reflects VC confidence) favor it, while its platform influences the ecosystem by de-risking drug development for "ovarian-in-a-dish" models, potentially accelerating therapies beyond fertility.[2][4][6] As a WEF Technology Pioneer, it bridges public-private efforts on healthcare equity.[1]
Gameto is poised to disrupt IVF with Fertilo's commercialization, expanding its platform to menopause and ovarian programs amid clinical successes and fresh 2025 funding.[3][4] Trends like AI-driven cell engineering, personalized medicine, and gender-focused biotech will propel it, with potential for global scaling if trials confirm efficacy. Its influence may evolve from niche innovator to reproductive health leader, redefining women's care from fertility to longevity—echoing its mission to put women and families first in a crisis too long ignored.[1][3]
Gameto has raised $117.0M across 5 funding rounds. Most recently, it raised $44.0M Series C in August 2025.
